Posted On: 07/24/2014 7:55:43 AM
Post# of 63801
$77 stock triples
Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial)
2014-07-22 16:20 ET - News Release
Neratinib Achieves Statistically Significant Improvement in Disease Free Survival
Company Plans to File for Regulatory Approval in First Half of 2015
O/Shares 30,117,819
Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial)
2014-07-22 16:20 ET - News Release
Neratinib Achieves Statistically Significant Improvement in Disease Free Survival
Company Plans to File for Regulatory Approval in First Half of 2015
O/Shares 30,117,819
(0)
(0)Scroll down for more posts ▼
